Annual Meeting2014: A Phase III trial Comparing MPT versus MPR In Newly Diagnosed Multiple Myeloma

Annual Meeting2014: A Phase III trial Comparing MPT versus MPR In Newly Diagnosed Multiple Myeloma

572 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Keith K. Stewart, MB ChB
Mayo Clinic
Scottsdale, Arizona, USA

E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM)

Melphalan, prednisone and thalidomide (MPT) is an accepted regimen in newly diagnosed MM. Early studies suggested that lenalidomide (R) might be substituted for thalidomide (T) with equal efficacy and less toxicity. We present E1A06, a randomized, multicenter phase 3 trial comparing MPT vs. MPR in pts with untreated, symptomatic, transplant ineligible MM.

Visit our website at: http://www.myeloma.org
Up Next Autoplay
>